Preladenant

Preladenant

Clinical data
Routes of administration	Oral
ATC code	none
Legal status
Legal status	Investigational
Identifiers
IUPAC name 2-(2-Furanyl)-7-[2-[4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]ethyl]7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine-5-amine
CAS Number	377727-87-2 N
PubChem CID	10117987
IUPHAR/BPS	5614
ChemSpider	8293510 N
UNII	950O97NUPO
KEGG	D09717
ECHA InfoCard	100.210.813
Chemical and physical data
Formula	C25H29N9O3
Molar mass	503.555 g/mol
3D model (JSmol)	Interactive image
SMILES COCCOc(cc4)ccc4N(CC3)CCN3CCn(c2nc1N)ncc2c(n5)n1nc5-c6occc6
InChI InChI=1S/C25H29N9O3/c1-35-15-16-36-19-6-4-18(5-7-19)32-11-8-31(9-12-32)10-13-33-23-20(17-27-33)24-28-22(21-3-2-14-37-21)30-34(24)25(26)29-23/h2-7,14,17H,8-13,15-16H2,1H3,(H2,26,29) N Key:DTYWJKSSUANMHD-UHFFFAOYSA-N N
NY (what is this?)

Preladenant (SCH 420814) was a drug that was developed by Schering-Plough which acted as a potent and selective antagonist at the adenosine A_2A receptor. It was being researched as a potential treatment for Parkinson's disease. Positive results were reported in Phase II clinical trials in humans, but it did not prove itself to be more effective than a placebo during Phase III trials, and so was discontinued in May 2013.